The mammalian ␤-like globin locus contains related genes that are expressed at different times during development. This developmentally regulated pattern of ␤-globin gene expression is known as globin gene switching (9, 68) . In humans, the first gene expressed in the cluster is ε-globin in the yolk sac, followed by a switch in expression to ␥-globin in the fetal liver. The second switch is then to ␤-globin within the bone marrow. In addition to their individual promoters, the expression of these globin genes is controlled by a far-upstream region called the locus control region (LCR), a region whose chromatin exhibits tissue-specific DNase hypersensitivity and boundary elements and whose subsequences behave as transcriptional enhancers (17) . The regulation of this large ␤-globin cluster is thought to occur in part by competition of each globin member promoter for interaction with the LCR that, in addition to an endogenous silencing mechanism, enables the expression of only one member at the right time in development. Over the years, a number of erythroid enriched proteins, such as GATA-1, EKLF (erythroid Krüppel-like factor), and NF-E2, have been identified and studied for their ability to bind to the globin promoter sequences and DNase hypersensitive sites (HSs) at the LCR (23, 44, 45) . EKLF is an erythroid-specific transcription factor that activates adult ␤-globin expression by binding to the CACCC element in the promoter (49) .
Until recently, the biological evidence for EKLF's function had been limited to its role in activating ␤-globin gene expression. For example, EKLF Ϫ/Ϫ murine embryos die at day 14.5 of gestation due to a lethal anemia that results from the failure to produce adult ␤-globin (beta major) transcripts at the time of the switch to definitive erythropoiesis (54, 59) . Further study also revealed a specific loss of developmentally relevant DNase I-accessible chromatin in the proximal ␤-globin promoter and at HS3 at the ␤-LCR (70, 74) . Since the degree of DNase I hypersensitivity of a given locus correlates with nucleosomal remodeling and chromatin accessibility, these findings suggested that EKLF plays a role in these processes at the ␤-globin locus in definitive erythroid cells.
However, a paradox that had emerged from the results of the expression and genetic studies came from the observation that EKLF's message is also expressed in primitive (yolk sac) erythroid cells and multipotential hematopoietic cell lines (67) , in spite of the knockout data suggesting that it is functionally required only for definitive erythropoiesis. In any case, a number of recent observations have begun to resolve this picture. First, the results of microarray analyses, followed by direct testing, indicate that there are a range of EKLF transcriptional activation targets in addition to adult ␤-globin that fall within heme-biosynthetic, erythroid membrane, and hemoglobin-interacting protein categories (20, 24, 27, 60) . Second, the results of careful phenotypic analyses reveal that EKLF-null primitive erythroid cells are not normal (20) . Third, the results of promoter (40) and prospective hematopoietic-cell analyses (22) indicate that EKLF is expressed prior to erythroid commitment, particularly within the megakaryocyte-erythroid progenitor. Fourth, EKLF interacts with corepressors, such as Sin3A, histone deacetylase 1, and Mi2␤ (12, 66) . Finally, EKLF inhibits megakaryopoiesis while at the same time promoting erythroid maturation and differentiation (22, 66) .
Because the EKLF protein is expressed in primitive and definitive erythroid cell populations, as well as in the megakaryocyte-erythroid progenitor, posttranslational modifications and the resultant changes in protein-protein interactions are likely critical for generating functionally altered EKLF states at different stages of embryonic development and/or hematopoietic differentiation. EKLF undergoes multiple modifications, including phosphorylation (56), sumoylation (66) , ubiquitination (61) , and acetylation (76, 77) , and some of these have been shown to alter EKLF protein-protein interactions (12, 66, 77) . Of particular relevance to the present study, the acetylation of EKLF occurs subsequent to its interaction with the acetyltransferases CBP and P300 at lysine residues 288 and 302 near its zinc finger domain (77) . The acetylation of EKLF at 288K is critical for the optimal transactivation of ␤-globin in transient assays (77) , and the results of in vitro studies show that this modification enhances its ability to recruit the large erythroid complex (ERC-1) that contains SWI/ SNF chromatin-remodeling proteins to the promoter (4), likely via its interaction with BRG1 (10, 33, 34) . The general conclusions about EKLF function gleaned from the results of the molecular studies have been supported in vivo, where the results of chromosome conformation capture assays have established that EKLF is crucial for the formation of the active chromatin hub at the ␤-locus (19). These observations are further supported by the results of studies showing that ablation of EKLF leads to the absence of CBP, BRG1, TBP, and RNA pol II at the ␤-globin promoter in vivo (7) . As a result, EKLF plays roles both in establishing the correct three-dimensional structure at the ␤-like globin locus and in activating the transcription of the adult ␤-globin gene. Although the results of transient assays and in vitro analyses are highly suggestive, it has not been verified that EKLF posttranslational modifications, particularly acetylation, are critical for these in vivo observation, at the endogenous ␤-like globin locus. In addition, the role of EKLF modification in its ability to recruit coactivators, open chromatin, and induce transcription in vivo has not been addressed.
For the present studies, we have developed a rescue system within a newly established EKLF-null erythroid cell line to address these issues. These have led to novel results regarding the importance of EKLF acetylation in these processes and to some unanticipated interactions with nucleosomal components that enable us to present a more-detailed model of EKLF's mode of action at the ␤-like globin locus.
MATERIALS AND METHODS

EKLF
؊/؊ cell line and manipulations. The 18SCF cell line was established from EKLF-null fetal livers after infection with the J2 retrovirus as described previously (14) . Briefly, embryonic day 12.5 (E12.5) EKLF Ϫ/Ϫ p53 Ϫ/Ϫ fetal liver cells were cultured at a density of 5 ϫ 10 5 cells/ml in the presence of 20% supernatant obtained from the culture of 2-J2 retroviral producer cells in I score's modified Dulbecco's medium (Gibco) with 10% fetal calf serum, 20% pokeweed mitogen-spleen conditional medium (21) , 250 ng/ml of stem cell factor (SCF) (Gibco), 0.3 U/ml of erythropoietin (Sigma-Aldrich), 1,000 U/ml of interleukin-3 (Gibco), and 1% penicillin-streptomycin (Sigma-Aldrich). After 72 h of fetal liver cell culture, many dividing cells formed "grapes" in suspension. These grapes of cells were picked and cultured individually. After expansion in the same medium, 10 out of 30 potential clones survived, and among these, two clones had characteristics of erythroid cells (cellular morphology and capacity to express ␣-globin).
The cell surface marker expression in actively growing 18SCF cells was monitored after staining with the following antibodies (Pharmingen): CD19-peridinin chlorophyll protein, B220-fluorescein isothiocyanate (FITC), CD3e-FITC, CD4-phycoerythrin (PE), CD41-FITC, CD11b-PE, Ly6G-FITC, CD71-PE, Ter119-PE, CD117-allophycocyanin, CD34-PE, and Ly6A/E-FITC. The cells were analyzed by using FACSCalibur (Becton Dickinson) and FlowJo (TreeStar). All gates were drawn based on negative controls for each sample. Cell morphology was assessed by examining the cells under a 100ϫ oil immersion objective after a cytospin and May-Grunwald Giemsa staining (Sigma).
Full-length wild-type or acetylation mutant EKLF was cloned into the EcoRI site of the murine stem cell virus-internal ribosome entry site-green fluorescent protein (GFP) (MIG) retroviral vector (72) . After calcium phosphate cotransfection with the pCL-Eco packaging vector (53) into 293T cells, the supernatant was used to infect 18SCF cells as described previously (26) . The GFP positivities correlated with EKLF mRNA and protein expression levels, and all experiments used clones that exhibited similar levels of wild-type or acetylation mutant protein (as in Fig. 1) .
Cell culture and stable line analyses. 293T or 745A murine erythroleukemic (MEL) cells were maintained in Dulbecco's modified Eagle's medium containing 10% serum and glutamine. MEL cell lines with short hairpin EKLF (shEKLF) were gifts from F. Morle (8) . Plasmids containing FLAG-H3.1 (kind gift from K. Wilson [51] ) or FLAG-H3.3 (kind gift from Y. Nakatani [69] ) were transfected into 293T or MEL cells by using FuGene 6 (Roche) or Tfx-50 reagent (Promega), respectively, according to the manufacturer's instructions. Stable clones in MEL cell lines were selected by increasing exposure to G418, expanded, and used for further experiments. RNA extraction and quantitative RT-PCR were performed as described previously (66) .
DNase hypersensitivity assay. Nuclei were prepared from 18SCF cells or infected and GFP-selected progeny carrying wild-type EKLF, 288K/R, 302K/R, or 288/302/K/R as described previously (57), followed by quantitation of the HS formation as described previously (46) . DNase I digestion conditions were selected after extensive preliminary experiments to determine the correct enzyme concentration and time of incubation.
ChIP. Chromatin immunoprecipitation (ChIP) was performed as described previously (28, 40) , with the following modifications. Briefly, 2 ϫ 10 6 cells were cross-linked in 1% formaldehyde at room temperature. The cells were sonicated, lysates were cleared by centrifugation, 10% was removed to serve as input, and the remaining material was incubated with the desired antibodies. Chromatin occupancy levels were quantified by real-time PCR measuring Sybr green (Qiagen) fluorescence relative to a titrated chromatin input standard curve. Primers were designed by using Primer Express software (Applied Biosystems), and their specificities were verified by showing that each primer pair generated a single amplicon and dissociation curve. The results were read with an ABI Prism 7900HT sequence detection system and analyzed with ABI software. Primer sequences are available on request.
In vitro pull-down assay. Core histones H2A, H2B, H3.3, and H4 (kind gifts from N. Mermod [3] ); glutathione S-transferase (GST)-tagged H3.3, H3.1, or various truncation mutants (50) ; and EKLF constructs were prepared as described previously (76) . GST-tagged H3.3 or H3.1 or various truncation mutants (50) and EKLF constructs were used as described previously (76) . Briefly, bacterial cells harboring the GST constructs were induced with isopropyl-␤-D-thiogalactopyranoside (IPTG). To isolate the overexpressed proteins, the cells were lysed by sonication in incubation buffer containing 50 mM Tris-HCl (pH 7.5), 200 mM NaCl, 0.1% NP-40, and protease inhibitors, cleared by centrifugation, and passed through a GST-Sepharose column. The column was washed with incubation buffer. The purified protein retained in the column was separated on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gels (Bio-Rad) and detected by Coomassie staining. For the pull downs, equal amounts of GST-fusion proteins coupled to glutathione Sepharose beads (final concentration, approximately 50 nM) were incubated with 10 l in vitro-translated [ 35 S]methionine protein (STP3 T7 kit; Novagen) overnight at 4°C in a total of 1 ml of incubation buffer. The beads were washed five times with incubation buffer containing 300 mM and 0.2% NP-40, boiled in SDS loading buffer, and electrophoresed on SDS-PAGE gels. All gels were exposed to EN 3 HANCE solution (NEN Life Science product), followed by detection by autoradiography.
RESULTS
Establishment of EKLF
؊/؊ erythroid lines. To facilitate our ability to monitor the in vivo effects of mutant EKLF proteins at endogenous loci, we generated an erythroid cell line that is deficient in EKLF and used these immortalized cells for rescue experiments. E13.5 fetal liver cells from EKLF-null embryos (59) were immortalized by infection with the J2 retrovirus (14) and expanded from clonally derived colonies. The selected clone, 18SCF, grows well in erythropoietin plus SCF. The results of fluorescence-activated cell sorter (FACS) analyses in-dicate that these cells do not express B-cell, T-cell, or megakaryocytic markers; that they exhibit some macrophage/ granulocyte expression; and that they express very high levels of CD71 but very low levels of Ter119 (Table 1) . They also express moderate levels of c-kit, CD34, and Sca-1. Morphological observations support these characteristics. As expected, EKLF is not expressed and ␤-globin levels are not detectable by semiquantitative reverse transcription-PCR (RT-PCR) (not shown). We have expanded the 18SCF line for up to 8 weeks for the present studies.
Reintroduction of EKLF and rescue of endogenous ␤-globin expression. We cloned wild-type EKLF and its derivatives containing mutations in each of its acetylation sites into a MIG vector (72) and prepared viral supernatants. We initially tested whether the 18SCF cells could be rescued by retroviral infection with the MIG EKLF retrovirus. We found that infection efficiency was quite low (ϳ1%) with the use of spinoculation or retronectin approaches with high-titer virus (Fig. 1A) . However, infected cells were sorted via the GFP marker, and these could be expanded for analysis for 2 to 3 weeks, after which the positive, EKLF-expressing population began to decrease (Fig.  1B) . Using this material, we found that ␤-globin expression is only observed in the EKLF-expressing cells (Fig. 1C) , thus providing us with a suitable rescue system.
We next addressed whether the acetylation mutants could rescue ␤-globin expression as successfully as wild-type EKLF. Extracts from each of the infected and sorted 18SCF populations express similar levels of EKLF protein and quantified message ( Fig. 2A and B) . We found that while mutation of 302K had a minimal effect on ␤-globin rescue, mutation of 288K (or the double mutant at 288/302/K/R) produced an essentially inactive EKLF (Fig. 2C ). These data show that the availability of 288K, but not of 302K, for acetylation is critical for the optimal transactivation ability of EKLF at the endogenous ␤-globin promoter. This supports the earlier observations derived from transient assays suggesting that the acetylation of lysine 288 is crucial for EKLF activity (76) but that the acetylation of lysine 302 is not critical for EKLF's function as an activator (12) . (2) . Our earlier studies had not shown any qualitative differences in DNA binding in vitro by any of the EKLF acetylation mutants to the CACCC sequence located at the Ϫ90 region of the ␤-major promoter (77) . Using the rescue system with 18SCF cells, we tested whether the wild type and the acetylation mutants of EKLF can bind to the ␤-major promoter equally well in vivo by using ChIP. We found that wild-type EKLF and the 302K/R mutant are enriched at the promoter (Fig. 3A) . However, occupancy by the 288K/R mutant and the 288/302/K/R double mutant at the ␤-globin promoter is virtually undetectable (Fig. 3A ). These results demonstrate that the availability of lysine 288 for acetylation plays a critical role in EKLF's ability to access its target site within chromatin in vivo, unlike the in vitro data with naked DNA. Since EKLF is acetylated at this residue by CBP, these data also imply that in vivo, DNA-bound EKLF must be highly enriched for its acetylated form. The EKLF-CBP interaction is crucial for EKLF's optimal function as an activator (77), and CBP is not present at the ␤-globin promoter in EKLF-null cells (7) . EKLF binds to CACCC sequences in HS2, HS3, and the ␤-major promoter (28) . With this in mind, we tested the recruitment of CBP to the ␤-globin region by using ChIP after EKLF rescue of 18SCF cells. We found that CBP is enriched at the ␤-major promoter, HS2, and HS3 regions only in lines expressing wild-type EKLF and the lysine 302 mutant, but not in the lines expressing lysine 288 and the double mutant (Fig. 3B) .
Considering that the SWI/SNF complex has been demonstrated to mediate chromatin remodeling by EKLF in vitro and that this is dependent on its acetylation status (4, 34, 77), we next tested whether the chromatin structure was affected in the rescued cells by performing an in vivo DNase I hypersensitivity assay. We focused on the status of chromatin remodeling at HS3 as indicative of the status of an active chromatin hub (19) and also because this site is lost in the absence of EKLF (71, 74) . Cells expressing wild-type and mutant EKLF were harvested, and the nuclei were digested with increasing amounts of DNase I. The DNA was subsequently purified, and the presence of HS3 was analyzed by using real-time PCR. The parental 18SCF cell line and the promoter of another gene (encoding Nf-M, a neurofilament subunit) not activated by EKLF served as negative controls. The results of these analyses demonstrate that rescue with wild-type EKLF leads to HS formation with HS3, as the rescued line is ϳ5-to 10-fold more sensitive to DNase I (i.e., fewer PCR amplicons remain after treatment, indicating an open chromatin structure) (Fig. 3C ). This is also observed after rescue with the EKLF 302K/R mutant (Fig. 3C) . However, rescue with EKLF 288K/R is virtually indistinguishable from the parental line (Fig. 3C) . The results of these studies demonstrate that the EKLF acetylation status, particularly at an available lysine 288 residue, is of primary importance for binding to DNA and for contributing to the ultimate formation of an open chromatin structure in vivo.
Altered acetylation of histone H3 at the ␤-globin promoter is dependent on EKLF. A major factor regulating the degree of chromatin folding is histone acetylation (65). As we found that there was less recruitment of CBP to the ␤-globin locus and less of an open chromatin structure at HS3 in the cells expressing 288K/R mutant EKLF, we also tested the status of histone acetylation at the ␤-major promoter and the LCR in two ways. First, we performed ChIP using pan-acetyl-H3 antibodies on the rescued 18SCF cell lines expressing wild-type or 288K/R, 302K/R, or 288/302/K/R mutant EKLF. We found that the ␤-globin promoter, as well the HS2 and HS3 sites, had a large enrichment of acetyl-H3 in cell lines expressing wild-type and 302K/R EKLF (Fig. 4A) . However, the lines expressing 288K/R and 288/302/K/R were similar to the negative controls and exhibited little, if any, acetyl-H3 enrichment (Fig. 4A) .
Second, we used an MEL cell line that contains a doxycyclin (49) . Since CBP acetylates histone H3 at lysine 14 (37), a prediction from our data is that loss of EKLF should result in a decrease in the level of histone H3 K14 acetylation due to the absence of CBP recruitment by EKLF. The stably modified MEL cells were grown for 2 days in the presence of 2 g/ml Dox to induce shEKLF. This treatment is sufficient to decrease EKLF message and protein and ␤-globin message levels by over 80% (8) . Terminal differentiation was then induced with DMSO to establish active transcription of the ␤-globin gene. After 4 days of differentiation, cells were subjected to ChIP using pan-acetyl-H3 and acetyl-H3 Lys14-specific antibodies. Consistent with the results of our rescue studies, we found that the decrease of EKLF protein levels led to a major loss of acetylated H3 protein at the promoter and HS2 and HS3 (Fig. 4B) . The histone acetylation status on the
FIG. 4. EKLF-dependent histone H3 acetylation at the ␤-globin locus. (A)
ChIP was performed to determine the status of histone H3 acetylation at the ␤-globin locus in 18SCF EKLF-null cell lines before and after rescue with wild-type or acetylation mutants of EKLF. ChIPs were performed in the absence or in the presence of pan-acetyl-H3 antibody (acH3) (product no. 17-615; Millipore). Histone modification associated with HS2 and HS3 of the LCR and the ␤-promoter (␤-major) was determined by quantitative real-time PCR. Ϫ, absent (Ab) or not infected (Rescue); WT, wild type. (B) MEL cells containing a stably integrated shEKLF construct were treated with 2 g/ml Dox for 48 h to induce its expression (which results in knockdown of EKLF levels to ϳ20% [8] ), followed by treatment with 1.5% DMSO to induce terminal differentiation. After 96 h, ChIP was performed either without antibody or in the presence of pan-acetyl-H3 antibody (acH3) (product no. 17-615; Millipore) or acetyl-histone H3 Lys14 antibody [acH3(lys14)] (product no. 07-353; Millipore), and modifications associated with HS2 and HS3 of the LCR and the ␤-promoter (␤-maj) were determined by quantitative real-time PCR. The results from three independent experiments have been averaged. Error bars show standard deviations. Ϫdox, without Dox; ϩdox, with Dox; IgG, immunoglobulin G; Ab, antibody.
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necdin gene remained unaltered, showing that this is not just a general effect. However, we found an even more profound loss of acetyl-H3 lys14 across all sites examined (Fig. 4B) . Together, these two sets of data with different cell lines demonstrate that the EKLF protein is critical for the establishment of the proper level of acetylated H3 at different regions of the ␤-globin locus and further establish that its interaction with and recruitment of CBP are critical for the downstream modification of lysine 14 of histone H3, thus confirming our hypothesis that EKLF recruits CBP to bring about modifications of the chromatin that favor transcription.
The EKLF zinc finger domain interacts with the aminoterminal tail of core histone H3. Our current results and previous observations indicate that acetylated EKLF influences chromatin structure and gene expression by recruiting chromatin modifiers, such as CBP, and remodelers, such as the SWI/SNF complex (4, 34) . In light of this, we can hypothesize that the core histones might provide a nucleosomal target for chromatin opening by EKLF. The interaction of other activators with nucleosomal components (3, 50) led us to test the interaction of EKLF with the core histone proteins (H2A, H2B, H3, and H4) by performing an in vitro pull-down assay using bacterially expressed, GST-tagged EKLF and individually in vitro-translated, [ 35 S]methionine-labeled core histone proteins. We find that EKLF preferentially interacts with core histone H3 (Fig. 5A) .
Four different histone H3 variants have been reported (H3.1, H3.2, H3.3, and CENPA) (63, 64) . A large number of recent studies have focused on the role of variant histones in marking transcriptional states. The histone variant H3.3 is incorporated into nucleosomes independent of DNA replication and is a potential mediator of epigenetic memory of the active transcriptional state (1, 13, 47) . However, the deposition of H3.1 is tightly coupled to DNA replication (1). Even though H3.1 and H3.3 differ by only five amino acids (41, 63) , four of these residues reside in their globular domain and could be crucial for their distinctive deposition in the chromatin and for their interaction with protein partners (69) . We had used the histone variant H3.3 in our initial experiment to investigate whether EKLF interacts with any of the core histone proteins. To see if EKLF also interacts with the core histone H3.1 and, also, to map the interaction domain of EKLF, we performed pull-down assays using either GST-tagged full-length EKLF protein, the GST-tagged EKLF proline domain, or the GSTtagged EKLF zinc finger domain, along with labeled, in vitrogenerated H3.1 or H3.3 protein. We found that EKLF interacts equally well with H3.1 and H3.3 and that the interaction is mediated via the zinc finger domain of EKLF (Fig. 5B) .
We next mapped the region of histone H3 that is responsible for its interaction with EKLF. In this case, we used the GSTtagged histone H3.3 tail or its globular domains and full-length EKLF and found interaction only with the amino-terminal tail (Fig. 5C ). Not surprisingly, a similar level of interaction is seen with the amino-terminal tail of histone H3.1. An analogous experiment performed between the zinc finger domain of EKLF and N-terminal or globular histone H3 domains also leads to the same conclusion (data not shown). Although at this level of resolution we see no evidence of discrimination between the two histones, we can conclude that EKLF specifically interacts with the amino-terminal region of histone H3 via its zinc finger domain.
The results of our studies show that EKLF interacts with CBP and that lysine 288 is necessary and important for this interaction. We have also shown that EKLF interacts with the N-terminal tail of histone H3 through its zinc finger domain. This prompted us to determine whether the EKLF acetylation mutant that is compromised in its ability to recruit CBP is also affected in its ability to interact with the histone. Additionally, since the zinc finger region of EKLF is also its DNA-binding domain, we wanted to determine whether the ability of EKLF to bind to DNA and interact with histone H3 can be uncoupled. For this we used a mutant EKLF that is compromised in its ability to bind to DNA (12) . Wild-type EKLF or 288K/R, 302K/R, or MZn1-3 (containing mutations that alter critical histidines known to be important for coordinating zinc within each finger) variants were cotransfected with either FLAGhemagglutinin (HA) H3.3 or FLAG-HA H3.1 in 293T cells. After coimmunoprecipitation using M2-agarose or immunoglobulin G and Western blot analysis using anti-EKLF antibody, we found that the wild type and mutants of EKLF all attain a similar in vivo level of interaction with histone H3.3 or H3.1 (Fig. 5D ). This enables us to conclude that neither the acetylation status nor the zinc finger structure of EKLF plays a role in its ability to interface with histone H3.
Distribution of histone H3.3 in mouse ␤-globin locus in MEL cells. It has been reported from studies with Drosophila melanogaster that although no specific posttranslational modification is restricted to either H3 variant, H3.3 is enriched in modifications associated with transcribed genes, including acetylation of lysine 14. In contrast, protein modifications associated with repressed genes are present on H3.1 (47) . In mammalian cell lines, H3.3 deposition is replication independent and occurs on actively transcribed genes, but not on silent loci (13, 16) . In a chicken hematopoietic cell lineage, however, there is no straightforward correlation between sites of H3.3 incorporation and active or repressive chromatin modifications (30) . To investigate this issue within the mammalian hematopoietic lineage, we constructed MEL cell lines that stably express either FLAG-HA-H3.1 or FLAG-HA-H3.3 (51, 69) . We screened individual colonies and pools for lines that expressed equal levels of the tagged protein (Fig. 6A) to rule out the possibility that increased or decreased levels of expression were responsible for any differential incorporation of one histone versus the other. We then used these lines to test the in by real-time PCR using primers specific for adult ␤-globin (␤-maj), embryonic ␤H1, embryonic ε-globin (Ey), and necdin promoters (see Fig. 3B ). All experiments were performed in triplicate. Error bars show standard deviations. Fl, FLAG; Ab, antibody; maj, major.
VOL. 28, 2008 EKLF ACETYLATION ESSENTIAL FOR ␤-GLOBIN GENE ACTIVATION 6167 vivo interaction of histone H3 variants with EKLF via coimmunoprecipitation. Similar to our in vitro results, we found that EKLF interacts at a comparable level with each H3 variant and that this level of interaction does not change after the induction of terminal differentiation and ␤-globin gene expression (Fig. 6A) . Finally, to test the relative distribution of H3.1 or H3.3 across the globin locus, we performed ChIP with MEL cells stably expressing H3.3 or H3.1 before and after treatment with DMSO to cause differentiation and the expression of adult ␤-globin. After 4 days, cells were collected and ChIP was performed using M2-agarose (FLAG antibody) to monitor the presence of the tagged H3 variant and pan-acetyl-H3 antibody to monitor the total (tagged and untagged) acetylated histone H3 detected under each condition within each cell line. We monitored occupancy at the embryonic ␤H1 and ε-globin (Ey) promoters and the adult ␤-major promoter for enrichment of either variant of histone H3. The necdin promoter served as a control as it is nonerythroid and should not be affected by the onset of erythroid differentiation. Under conditions in which pan-acetyl-H3 is enriched in both cell lines, we found that only H3.3 is enriched on the adult ␤-major promoter after the differentiation of MEL cells, but not on the embryonic ␤H1 or ε-globin promoters (Fig. 6B ). This suggests that, similar to the results of studies showing a differential utilization of histone H3 variants, histone H3.3 is specifically enriched during active transcription of the ␤-like globin locus in the erythroid lineage.
DISCUSSION
Sequence-specific DNA-binding transcription factors utilize various molecular mechanisms to modulate chromatin architecture and recruit the basal transcription machinery (35, 39, 52) . Here we propose a mechanism by which a lineage-restricted transcription factor regulates the formation of tissuespecific chromatin domains. For this study, we used an EKLF Ϫ/Ϫ fetal liver cell line, in combination with retroviral rescue of its biologically relevant target, to explore how the acetylation of EKLF contributes to its chromatin remodeling ability at the adult ␤-globin locus in vivo. By focusing on effects at the endogenous locus, this system avoids the deficiencies of using a nonchromatinized reporter assay with overexpressed transfected constructs. Given EKLF's critical role in erythroid gene regulation, this is a particularly good model system in which to study chromatin remodeling and the transcriptional competence of the ␤-globin locus.
Acetylation of EKLF is essential for transcription and chromatin remodeling. Our laboratory has previously demonstrated that EKLF binds to CBP (76, 77) , a cofactor whose acetyltransferase activity results in the acetylation of EKLF at two specific sites, lysine 288 and lysine 302. CBP also acetylates histone H3 (37) . We find that these effects are interrelated, as the CBP-dependent acetylation of EKLF at 288K is itself necessary for the recruitment of CBP to the ␤-globin promoter, an association that remains critical for its subsequent acetylation of histone H3 at lysine 14. Consistent with this is the fact that in the absence of EKLF, the acetylation of histone H3 at lysine 14 is more profoundly affected. This suggests that EKLF must interact with and be modified by CBP prior to its binding to DNA and that the ability of CBP to modify both transcription factor and histone substrates is equally necessary for recruitment and their proper arrangements at the locus. The acetylation of EKLF lysine 288 also provides a more-efficient substrate for EKLF association with the SWI/SNF chromatin remodeling complex (4, 77) , likely by means of its interaction with the BRG1 component (10, 33, 34) . Coupled with the observation that histone H3 acetylation at lysine 14 aids in the recruitment of TFIID (73), the result is the formation of a transcriptionally competent, three-dimensional epigenetic protein/DNA complex that has been called the "active chromatin hub" (18, 19) .
DNA binding by EKLF in vivo is affected by acetylation. The acetylation of transcription factors can affect their DNA-binding ability, nuclear localization, protein stability, or proteinprotein interactions (36, 38) . Abolishment of the acetylation sites in EKLF has no effect on nuclear localization or protein stability (61, 62) , and the acetylation status of EKLF does not affect its interaction with DNA in vitro (77) . Yet, unexpectedly, we now show that mutation at the critical 288K acetylation site alters EKLF's interaction with chromatin in vivo. This suggests that the mode of binding by EKLF to naked DNA in vitro is different from its mode of binding to chromatinized templates in vivo. Similar results have been obtained with GATA-1, where lack of acetylation leads to differential binding with chromatinized or naked templates (38) . It is relevant to note that other mutations in GATA-1 that do not affect its binding to DNA also show diminished chromatin occupancy at some sites in vivo (32) .
A model for sequential epigenetic modification and transcriptional activation. The carboxy-terminal DNA-binding domain (amino acid residues 293 to 376) of EKLF is sufficient to induce complete chromatin remodeling of a ␤-promoter template in vitro (4) . We have shown that this region of EKLF also binds to histone H3. Furthermore, this interaction does not require an intact zinc finger structure, suggesting that the binding of EKLF to histone and DNA can occur independently of each other. The chromatin of the ␤-like globin cluster is open well before the onset of transcription (6, 29) . Together, these observations raise the possibility that EKLF might be playing a DNA-independent role at this early stage and compels us to consider a model that is surprising but consistent with our observations. Our hypothesis is that EKLF interacts with CBP, is acetylated by it, and recruits it to the globin promoter. EKLF directly interacts with histone H3 and thus serves as a bridge or adapter between CBP and histone H3, facilitating the interaction between the two. This in consequence leads to active histone modifications (acetylation) and subsequent chromatin remodeling at the locus, all of which occurs in the absence of direct DNA binding by EKLF. Only after the remodeling has occurred can EKLF fully access and bind to its cognate DNA (CACCC) element at the ␤-major promoter, thus further stabilizing the active chromatin structure (hub) and ultimately leading to gene transcription. This process cannot begin in the absence of CBP acetylation of EKLF 288K and cannot finish without direct recognition of the DNA by EKLF. Alternatively, acetylated 288K may itself be required for the stable association of EKLF binding to chromatinized DNA at the promoter, with this initial stable association being necessary for subsequent remodeling and transcription (42, 43) . Since the amino terminus of the histone proteins is the main site for posttrans-lational modifications, the interaction of EKLF with the aminoterminal tail of histone H3 supports our idea that physical interaction between EKLF and the H3 tail is required for its acetylation and is a prerequisite for gene transcription. This model also raises the possibility that EKLF/CBP is part of a larger EKLF-containing protein complex that may contain (an)other DNA-binding protein(s). Ordered recruitment can be accomplished in multiple ways depending on the gene that is to be regulated (15) , and the dynamic nature of histone modifications and ATP-dependent nucleosomal sliding at the promoter (48) lend credence to these ideas. Our model is also broadly consistent with the results of recent GATA-1 rescue studies (reviewed in reference 75).
Other proteins that bind the EKLF zinc fingers do not necessarily require an intact structure for this interaction. For example, Sin3A/histone deacetylase 1 binds EKLF and aids its repression activity in the absence of an EKLF finger structure (12) , and EKLF nuclear import is (mostly) retained in the absence of an EKLF finger structure that constitutes its major nuclear localization signal (58, 62) .
Genetic manipulation of CBP and BRG1 demonstrate that they are essential for erythroid development (5, 11, 25, 55) . Their requirement can be explained (at least in part) by the results of our present studies, where we have found at a molecular level that CBP is responsible for EKLF and histone H3 acetylation, steps that we suggest are needed for the ultimate chromatin remodeling catalyzed by SWI/SNF that occurs at the ␤-like globin locus. At the same time, the recruitment of CBP to the locus will not occur in the presence of EKLF that cannot be itself acetylated by CBP at 288K. As a result, CBP's ability to transfer acetyl groups both to histones and to transcription factor substrates is critically important for successful gene activation. Such covalent modifications contribute significantly to the overall mechanism of transcriptional activation at specific genes and help explain the vital role of CBP in this process.
The binding of EKLF to histone H3 led us to examine the interaction of EKLF with the two best-characterized H3 variants. Since H3.3 is the histone protein associated with actively transcribing DNA, it seemed reasonable that EKLF should preferentially interact with it. But under the conditions tested, either in vitro, in transient transfection, or in stable lines, we did not find this to be true. However, using tagged H3.3 and H3.1 stable lines to monitor whether either of the H3 proteins was preferentially recruited to the ε-globin, ␤-H1, and necdin promoters (all transcriptionally inactive in differentiated MEL cells) and the ␤-major promoter (transcriptionally active in differentiated MEL cells), we found enrichment of H3.3, but not H3.1, at the actively transcribing gene, similar to that seen at other promoters (13) and consistent with the idea that the intrinsically less stable H3.3-containing nucleosome is preferentially incorporated at gene-transcribing regions (31) . The further study of the effects of this and other histone variants on ␤-like globin gene expression and whether EKLF plays any role in this differential recruitment will allow us to ultimately distinguish various mechanisms of promoter activation that may be operant across the locus and that lead to its precise developmental regulation.
